Skip to main navigation
Skip to content
Opiant_logo Opiant
Main Menu
  • Contact
  • Careers
  • About
    • Corporate Overview
    • Management Team
    • Board of Directors
    • Medical Advisory Board
    • Media
    • Careers
      • Culture at Opiant
  • Science & Technology
    • The Science of Addiction
    • Opioid Antagonists
    • Nasal Spray Delivery Technology
    • Antagonist for Acute Cannabinoid Overdose
    • Intellectual Property
    • Publications
  • Addiction Disorders
    • Overview
    • Opioid Use Disorder
    • Alcohol Use Disorder
    • Cannabinoid Use Disorder
  • Products & Pipeline
  • Patients & Families
    • Overview
    • Clinical Trials
    • External Resources
  • Investors
    • Stock Information
      • Stock Quote & Chart
      • Historical Price Lookup
      • Investment Calculator
      • Analyst Coverage
    • News Releases
    • Events and Presentations
    • Corporate Governance
      • Board of Directors
      • Board Committees
      • Governance Documents
    • Financials & Filings
      • SEC Filings
      • Annual Reports & Proxy Statements
    • Investor Resources
      • Information Request
      • Contact IR
      • Email Alerts

Investors

SEC Filing Details

SEC Filing Details

Document Details

Form
SB-2/A
Filing Date
Jan 23, 2007
Document Date
Jan 23, 2007
Form Description
Pre-effective amendment to an SB-2 filing
Filing Group
Registration Statements
Company
Opiant Pharmaceuticals, Inc.
Issuer
Opiant Pharmaceuticals, Inc.

Filing Formats

View HTML
Download PDF
Download DOC
Download XLS
Print Page
RSS Feeds
Email Alerts
Contact IR

  • Privacy Policy
  • Site Map
© Opiant, 2020. All Rights Reserved.